Chikungunya Market Projected To Surpass $1 Billion By 2030 At 9.1% CAGR

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Larger Will The Chikungunya Market Become By 2030 Compared To 2026?

The chikungunya market has observed substantial growth in recent years. It is anticipated to increase from $0.65 billion in 2025 to $0.71 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.4%. Key drivers for this growth in previous periods include an elevated incidence of mosquito-borne viral infections, the expansion of endemic areas influenced by climate variability, the restricted availability of approved vaccines, a strong reliance on symptomatic treatment methods, and public health monitoring initiatives.

The chikungunya market is anticipated to experience substantial expansion over the next few years. It is projected to reach $1 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.1%. This growth during the forecast period is fueled by several factors, including escalating investments in vaccine research, a heightened emphasis on preventive healthcare, the broadening of vector control initiatives, increasing demand for prompt diagnostic tools, and enhanced global health funding directed towards emerging diseases. Key trends expected throughout this period encompass the accelerated development of chikungunya vaccines, the wider adoption of antiviral treatment strategies, an increased focus on early disease detection, the expansion of supportive care options, and improved surveillance efforts for mosquito-borne illnesses.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21137&type=smp

Which Core Factors Are Supporting The Expansion Of The Chikungunya Market?

The increasing occurrence of mosquito-borne diseases is projected to drive the expansion of the chikungunya market. These illnesses, including chikungunya, dengue, and zika virus, are transmitted to humans by infected Aedes mosquitoes and pose considerable global public health challenges. The rising worldwide incidence of such diseases is attributable to factors like climate change, urbanization, deforestation, stagnant water accumulation, inadequate vector control strategies, increased international travel, and insecticide resistance. Chikungunya treatment aids patients suffering from mosquito-borne diseases by alleviating symptoms such as fever, joint pain, and inflammation, thereby enhancing overall comfort and mobility, reducing complication risks, and promoting recovery through hydration, pain management, and supportive care. For example, in December 2024, the UK Health Security Agency, a UK-based government body, reported that dengue cases among returning travelers in England, Wales, and Northern Ireland surged to 473 between January and June 2024. This marked a 201% increase compared to the 157 cases recorded during the identical period in 2023. Thus, the escalating global incidence of mosquito-borne diseases is propelling the growth of the chikungunya market.

How Is The Chikungunya Market Structured Across Different Market Segments?

The chikungunya market covered in this report is segmented –

1) By Type: Antiviral Drugs, Herbal And Complementary Treatments, Supportive Care, Vaccines

2) By Product Form: Liquid Form, Powder, Solid Form

3) By Disease Stage: Acute, Chronic, Post-Infection

4) By Sales Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Supermarkets

5) By End User: Caregivers, Healthcare Professionals, Patients

Subsegments:

1) By Antiviral Drugs: Nucleoside Analogues, Protease Inhibitors

2) By Herbal And Complementary Treatments: Ayurvedic Remedies, Homeopathic Treatments, Traditional Chinese Medicine

3) By Supportive Care: Pain Relievers (NSAIDs, Acetaminophen), Fluid Therapy, Physiotherapy

4) By Vaccines: Live-Attenuated Vaccines, Inactivated Vaccines, mRNA-Based Vaccines

Which Trends Are Influencing The Expansion Of The Chikungunya Market?

Leading companies in the chikungunya market are concentrating on creating novel vaccines to boost immunity, prevent disease outbreaks, and tackle the increasing global health impact of chikungunya virus infections. A live attenuated chikungunya vaccine employs a reduced-strength version of the chikungunya virus to trigger an immune response without inducing the illness, thereby offering sustained defense. As an illustration, in November 2023, Valneva SE, a French biotechnology firm, disclosed IXCHIQ, a live attenuated chikungunya vaccine that received approval from the US government agency, the Food and Drug Administration (FDA). This particular approval was granted under an accelerated process, predicated on anti-CHIKV neutralizing antibody titers, with ongoing approval subject to confirmation of clinical benefits through subsequent studies. Valneva obtained a Priority Review Voucher (PRV) from the FDA, which the company plans to sell to fund its research and development initiatives. Ixchiq is administered via a single intramuscular injection and incorporates a live, attenuated form of the chikungunya virus, which might induce symptoms in individuals resembling those of chikungunya illness.

Who Are The Companies Shaping The Chikungunya Market Landscape?

Major companies operating in the chikungunya market are F Hoffmann-La Roche Ltd, Merck & Co Inc, Takeda Pharmaceutical Company Limited, Evotec SE, Valneva SE, Vaxart Inc, Inovio Pharmaceuticals Inc, Bharat Biotech International Limited, Moderna Inc, Emergent BioSolutions Inc, GlaxoSmithKline plc, Sanofi Pasteur, Instituto Butantan, Indian Immunologicals Limited, Zydus Lifesciences, BioNTech SE, Novavax Inc, Bavarian Nordic A S, Auro Vaccines LLC, Najit Technologies Inc, Clayton Biotechnologies Inc, Medigen Vaccine Biologics Corp

Access The Complete Chikungunya Market Report:

https://www.thebusinessresearchcompany.com/report/chikungunya-global-market-report

Which Area Represents The Largest Portion Of The Chikungunya Market?

North America was the largest region in the chikungunya market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chikungunya market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Chikungunya Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=21137&type=smp

Browse Through More Reports Similar to the Global Chikungunya Market 2026, By The Business Research Company

Chemotherapy Induced Anemia Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

Chemotherapy Induced Myelosuppression Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-myelosuppression-treatment-global-market-report

Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-peripheral-neuropathy-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795